UK
Health analytics
Real-world evidence generation
We work with our clients to generate rigorous and impactful real-world evidence. Our approach is grounded in high quality science, combining expertise in epidemiology, statistics, and real-world health data with modern data science methods and ways of working.
Our team works closely with clients to navigate and address the increasingly complex need for real evidence from healthcare professionals, payers, and Health Technology Assessment (HTA) organizations, regulators, and policymakers.
We use both traditional and cutting-edge real-world data sources
In today’s competitive and fast-changing market, the right Real-World Evidence (RWE) can accelerate approvals, strengthen market access, and drive adoption. We help you get there.
Our scientists combine rigorous RWE methodology with deep, hands-on knowledge of the world’s most trusted health data sources from the US (e.g. COTA, NHANES, commercial claims, disease registries), UK (e.g. Discover, CPRD, UK Biobank, NCRAS) and EU (e.g. EMR and registries).
This global reach means we can find the right data for your objectives, whether you’re pursuing regulatory submissions, building HEOR models, or demonstrating value to payers and providers. The result: evidence that is credible, defensible, and impactful where it matters most.
We support clients with RWE design and execution across the medicines development lifecycle:
- Burden of illness and other payer-focused evidence studies
- Comparative effectiveness
- Natural history of disease
- Pharmacovigilance and drug safety
- Drug utilization
- Advanced epidemiological study designs such as real-world comparators
- Development and validation of statistical and AI/ML models
- Impact evaluations
How evidence is communicated is critical in making sure that key messages are shared accurately and with impact. Our team has authored hundreds of peer-reviewed publications across many therapy areas, including in leading journals (The Lancet, The BMJ, PLOS Medicine, etc), using innovative data visualizations and technology to communicate evidence.
Medicines Nexus™
Prescription analytics platform
Our innovative prescription analytics platform delivering cutting-edge insights into the medicines market.
Featured insights
LCP Health Analytics partners with COTA to advance the use of US RWD
With recognition that European patients may be underserved by delays in accessing new health technologies, this initiative explores whether deidentified US patient data can be used to inform decisions and accelerate access.
LCP Health Analytics presence at the ISPE 2025 Annual Meeting
Read about the presentations and posters of our pioneering work that we shared at at the leading conference for pharmacoepidemiology.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Get in touch
Contact us to learn more about how we can provide clarity and insight in today’s increasingly complex life sciences and healthcare environment.
